Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for life science research and clinical diagnostics. With a focus on quality and customer service for over 65 years, its products advance the discovery process and improve healthcare, including several applications in the liquid biopsy space. Further bolstering its presence
For assessing cfDNA and ctDNA in liquid biopsies, Droplet Digital PCR (ddPCR) offers unrivaled detection, precision, and absolute quantification of target molecules. Digital Droplet technology partitions samples into thousands of microfluidic “droplet” test tubes, providing extremely sensitive and accurate digital answers for liquid biopsy research. ddPCR is regarded as the gold standard for orthogonal validation of variant allele frequencies and facilitates rapid turnaround with lower cost per targeted test.
For assessing CTC phenotype and discerning overall tumor prognosis, Celselect Slide™ Technology utilizes the Genesis system to process liquid biopsies for CTC enrichment and enumeration. It has been designed for use in academic, clinical, and pharmaceutical labs that seek to study rare populations of cells within complex heterogeneous samples. It can facilitate retrieval of isolated cells to be used in additional methods of analysis for proteomic and genomic expression or perform immunohistochemical staining. The system is designed around an open platform for user developed assays, markers, and automated microscopy and counting algorithms.
Together, Bio-Rad’s ddPCR and Celselect Slide™ Technologies offer a synergistic and unparalleled degree of insight into both cellular heterogeneity of CTCs as well as the ever growing need to understand their unique biomolecular signatures.
Celselect Slides™ and the Genesis System are for research use only. Not for use in diagnostic procedures.
For assessing cfDNA and ctDNA in liquid biopsies, Droplet Digital PCR (ddPCR) offers unrivaled detection, precision, and absolute quantification of target molecules. Digital Droplet technology partitions samples into thousands of microfluidic “droplet” test tubes, providing extremely sensitive and accurate digital answers for liquid biopsy research. ddPCR is regarded as the gold standard for orthogonal validation of variant allele frequencies and facilitates rapid turnaround with lower cost per targeted test.
For assessing CTC phenotype and discerning overall tumor prognosis, Celselect Slide™ Technology utilizes the Genesis system to process liquid biopsies for CTC enrichment and enumeration. It has been designed for use in academic, clinical, and pharmaceutical labs that seek to study rare populations of cells within complex heterogeneous samples. It can facilitate retrieval of isolated cells to be used in additional methods of analysis for proteomic and genomic expression or perform immunohistochemical staining. The system is designed around an open platform for user developed assays, markers, and automated microscopy and counting algorithms.
Together, Bio-Rad’s ddPCR and Celselect Slide™ Technologies offer a synergistic and unparalleled degree of insight into both cellular heterogeneity of CTCs as well as the ever growing need to understand their unique biomolecular signatures.
Celselect Slides™ and the Genesis System are for research use only. Not for use in diagnostic procedures.
